Minakem Generic APIs Minakem Generic APIs

X
[{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals for Rose Bengal Disodium

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            PV-10 (rose bengal sodium) Percutaneous intralesional injection, which is investigated in combination with standard of care immune checkpoint blockade (CB) for the treatment of Metastatic Uveal Melanoma.

            Lead Product(s): Rose Bengal Disodium,Pembrolizumab

            Therapeutic Area: Oncology Product Name: PV-10

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY